Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 in healthy subjects (SAD/MAD)
NCT03384823Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zelicapavir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety measured by adverse events, physical exams, vital signs, ECGs and clinical lab results at 8 days. Started Dec 2017; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03384823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384823.